Alphamab Oncology (HKG:9966) said JSKN003 received approval from the Center for Drug Evaluation of China's National Medical Products Administration to initiate a phase III clinical study, according to Friday filing with the Hong Kong bourse.
JSKN003 is a HER2-targeting ADC (antibody-drug conjugate) that combines a topoisomerase I inhibitor with KN026 (a humanized anti-HER2 bispecific antibody) used to treat tumors. The drug linker is attached specifically to the antibody's N-glycosylation site using glycoside-specific conjugation, the filing added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。